Establishing bioequivalence for inhaled drugs; weighing the evidence

Bibliography

• The Montreal Protocol. The Montreal protocol on substances that deplete the ozone layer. Final act (Nairobi: UNEP 1987. Fed Reg 1994;59:56276-98
   Google Scholar
• Stewart BA, Ahrens RC, Carrier S, Demonstration of in vivo Bioequivalence of generic albuterol metered dose inhaler to Ventolin. Chest 2000;117(3):714-21
   PubMed Web of Science ®Google Scholar
• Hindle M, Newton DA. Chrystyn H. investigation of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax 1993;48:607-10
   PubMed Web of Science ®Google Scholar
• Hindle M, Chrystyn H. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation method and spacer devices. Thorax 1994;49:549-53
   PubMed Web of Science ®Google Scholar
• Hindle LM, Newton DA, Chystyn H. Dry powder in-halers are bioequivalent to metered dose inhalers: a study using a new urinary albuterol (salbutamol) assay technique. Chest 1995;107:629-33
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Interim guidance for documentation of In vivo bioequivalence of albuterol aerosols (metered-dose inhalers. Rockville, MD: Division of bioequivalence. Office of generic drugs, food and drug administration; January 27, 1994; Publication No. 1-27
   Google Scholar
• Chystyn H. Standard for bioequivalence of inhaled products. Clin Pharmacokinet 1994;26:1-6
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use. (2007). Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD. Draft. CPMP/EWP/4151/00 Rev 1
   Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents.. Doc Ref. CPMP/EWP/4151/00 Rev.1. 22 January 2009 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003504.pdf [Accessed 30 August 2010]
   Google Scholar
• Healthy Canada. Release of Draft Guidance Document: Submission Requirements for Subsequent Market Entry Inhaled Corticosteroid Products for Use in the Treatment of Asthma. 2 August 2007. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/inhal_corticost-eng.pdf [Accessed 30 August 2010]
   Google Scholar
• Adams WP, Ahrens RC, Chen M-L, Demonstrating bioequivalence of locally acting orallyinhaled drug products (OIPs): workshop summary report. J Aerosol Med Pulm Drug Deliv 2010;23:1-29
   PubMedGoogle Scholar
• Respiratory Drug Delivery. ILISBN: Book 1, 1-933722-41-X: In: Dalby RN, Byron PR, Peart J, editors. FloridaDavis Healthcare International Publishing; Orlando, River Grove: 2010; vii
   Google Scholar
• Respiratory Drug Delivery Online. Available from: http://www.rddonline.com/index.php [Accessed 19 January 2011]
   Google Scholar
• International Society for Aerosols in Medicine/International Pharmaceutical Aerosol Consortium on Regulation and Science Workshop in Frankfurt, 12–13 Oct 2010. Available from: http://isam-org.activaero.de/component/content/article/13/38-ipac [Accessed 19 January 2010]
   Google Scholar
• Lee SL, Adams WP, Li BV, In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases. AAPS J 2009;11:414-23
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use. European medicines agency. 2008). “Guideline on the investigation of bioequivalence,” Draft. CPMP/EWP/QWP/1401/98 Rev 1
   Google Scholar
• Product Quality Research Institute workshop on demonstrating bioequivalence of locally acting orally inhaled drug products. Available from: http://www.pqri.org/workshops/imagespdfs/Bioequivalence2009_Final_Agenda.pdf [Accessed 19 January 2011]
   Google Scholar
• Dissanayake S. Application of the EU Guidelines for pharmacokinetic studies of locally acting orally inhaled drug products. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM. editors. Respiratory Drug Delivery. ISBN: Book 1, 1-933722-41-X: David Healthcare International Publishing; Orlando Florida, River Grove IL; 2010. p. 293-304
   Google Scholar
• Ehtezazi T, Horsfield MA, Barry PW, Dynamic change of the upper airway during inhalation via aerosol delivery devices. J Aerosol Med 2004;17:325-34
   PubMedGoogle Scholar
• Dolovich M, Rhem R. Impact of oropharyngeal deposition on inhaled dose. J Aerosol Med 1998;11:S112-15
   Google Scholar
• Newhouse MT, Dobranowski JA, Chambers C, Development and preliminary validation studies with an ex-vivo oropharyngeal model. In: Byron PR, Dalby RN, Farr SJ, editors. Proceedings of Respiratory Drug Delivery VI. Interpharm Press, Inc., Buffalo Grove, IL.1998, p. 389-91
   Google Scholar
• Cheng Y-S, Zhou Y, Chen BT. Particle deposition in a cast of human oral airways. Aerosol Sci Tech 1999;31:286-300
   Web of Science ®Google Scholar
• Burnell PKP, Asking L, Borgstrom L, Studies of the human oropharyngeal airspaces using magnetic resonance imaging IV – the oropharyngeal retention effect for four inhalation delivery systems. J Aerosol Med 2007;20:269-81
   PubMedGoogle Scholar
• Olsson B, Berg E, Svennsson M. Comparing aerosol size distributions that penetrate mouth-throat models under realistic inhalation conditions. In: Dalby RN, Byron PR, Peart J, editors. Respiratory Drug Delivery. David Healthcare International Publishing; Orlando Florida, River Grove IL; 2010. p. 225-33
   Google Scholar
• Raid AAM, Tarsin WY, Assi KH, Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Resp Med 2007;101:2395-401
   PubMed Web of Science ®Google Scholar
• Tarsin W, Assi KH, Chrystyn H. In-vitro inhalation flow rate dependent dosage emission and inconsistency from a combination of budesonide and efometrol in a dry powder inhaler. J Aerosol Med 2004;17:25-32
   PubMedGoogle Scholar
• Malton A, Sumby BS, Smith IJ. A comparison of in vitro drug delivery from two multi-dose powder inhalation devices. Eur J Clin Res 1995;7:1-17
   Google Scholar
• Prime D. Determining flow and flow acceleration conditions for in-vitro testing of dry powder inhalers. Abstracts from international society of aerosols in medicine, 15th congress; Perth; 2005, p. P68
   Google Scholar
• Mitchell J, Newman S, Chan H-K. In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review. AAPS PharmSciTech 2007;8:Article 110
   Google Scholar
• Bisgaard H, Klug B, Sumby BS, Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998;11:1111-15
   PubMed Web of Science ®Google Scholar
• de Boer AH, Bolhuis GK, Gjaltema D, Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers - Part 3: the effect of flow increase rate (FIR) on the in vitro drug release from the Pulmicort 200. Turbuhaler 1997;11:67-77
   Google Scholar
• Finlay WH, Gehmlich MG. Inertial sizing of aerosol inhaled from two dry powder inhalers with realistic breath patterns versus constant flow rates. Int J Pharm 2000;210:83-95
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Parkins DA, Thomas MJ, Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry powder inhalers delivering a combination of salmeterol 50 mug and fluticasone propionate 250mug: implications for establishing bioequivalence of inhaled products. Clin Ther 2009;31:370-85
   PubMed Web of Science ®Google Scholar
• Daley-Yates P. The clinical utility of pharmacokinetics: theoretical consideration across drug classes. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM. editors. Respiratory Drug Delivery. ISBN: Book 1, 1-933722-41-X: David Healthcare International Publishing; Orlando Florida, River Grove IL: 2010. p. 273-84
   Google Scholar
• Persson G, Ankerst J, Gillen M, Relative systemic availability of budesonide in patients with asthma after inhalation from two dry powder inhalers. Curr Med Res Opin 2008;24:1511-17
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Pearlman DS, de Guia T, Evaluation of efficacy, safety, and pharmacokinetics of budesonide delivered via two dry powder inhalers. Curr Med Res Opin 2008;4:1497-510
   Google Scholar
• Lahelma S, Kirjavainen M, Kela M, Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. Br J Clin Pharmacol 2004;59:167-73
   Web of Science ®Google Scholar
• Tukiainen H; on behalf of the Finnish Study Group. Safety, tolerability and acceptability of two dry powder inhalers in the administration of budesonide in steroid-treated asthmatic patients. Respir Med 2002;96:221-9
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Bagen S, Tournant J, Beclomethasone dipropionate chlorofluorocarbon and hydrofluoroalkane metered dose inhalers: relationship between systemic exposure, dose, fine particle mass and particle size in healthy volunteers. Eur Resp J 1999;14:1358
   PubMedGoogle Scholar
• Falcoz C, Horton J, Mackie AE, Pharmacokinetics of inhaled fluticasone propionate delivered via the Diskhaler and Diskus delivery devices in patients with mild to moderate asthma. Clin Pharmacokinet 2000;39(Suppl 1):31-7
   PubMedGoogle Scholar
• Kunka R, Andrews S, Pimazzoni M, Dose proportionality of fluticasone propionate from hydrofluoroalkane inhalers and comparability with chlorofluorocarbon inhalers. Resp Med 2000;94(Suppl B):10-16
   PubMedGoogle Scholar
• Clearie KL, Williamson PA, Vaidyanathan S, Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer. Br J Clin Pharmacol 2010;69:637-44
   PubMed Web of Science ®Google Scholar
• Johnson M. Fluticasone propionate: pharmacokinetic and pharmacodynamic implications of different aerosol delivery systems. In: Byron PR, Dalby RN, Farr SJ. editors. Respiratory Drug Delivery VI. Interpharm Press, Inc; Buffalo Grove, IL: 1998. p. 61-70
   Google Scholar
• Mackie AE, McDowall JE, Falcoz C, Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy subjects. Clin Pharmacokinet 2000;39(Suppl 1):23-30
   PubMedGoogle Scholar
• Noltinga A, Sistab S, Abramowitza W. Flunisolide HFA vs Flunisolide CFC:. Pharmacokinetic comparison in healthy volunteers. Biopharm Drug Dispos 2001;22:373-82
   PubMed Web of Science ®Google Scholar
• Lawrence M, Wolfe J, Webb DR, Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am J Respir Crit Care Med 1997;156:744-51
   PubMed Web of Science ®Google Scholar
• O'Connor D, Adams WP, Chen M-L, Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. J Aerosol Med Pulm Drug Deliv 2011;24:1-17
   PubMedGoogle Scholar